TFF Pharmaceuticals announces preclinical data published on TFF technology
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Sep 26 2024
0mins
Positive Preclinical Data: TFF Pharmaceuticals has published promising preclinical results in the Journal of Drug Delivery Science and Technology, supporting its TFF technology for formulating dry powders for pulmonary drug delivery.
Comparison with Other Technologies: The study shows that TFF inhalational dry powders outperform jet-milling and spray-drying methods in a rat model, demonstrating better drug distribution in the lungs and faster particle movement.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
